EP1693673A2 - Nachweis von Autoantikörpern von Pantienten mit rheumatischer Arthritis - Google Patents

Nachweis von Autoantikörpern von Pantienten mit rheumatischer Arthritis Download PDF

Info

Publication number
EP1693673A2
EP1693673A2 EP06114882A EP06114882A EP1693673A2 EP 1693673 A2 EP1693673 A2 EP 1693673A2 EP 06114882 A EP06114882 A EP 06114882A EP 06114882 A EP06114882 A EP 06114882A EP 1693673 A2 EP1693673 A2 EP 1693673A2
Authority
EP
European Patent Office
Prior art keywords
cit
peptide
amino acid
peptides
xnong
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP06114882A
Other languages
English (en)
French (fr)
Other versions
EP1693673A3 (de
Inventor
Waltherus Van Venrooij
Jan Drijfhout
Martinus Van Boekel
Gerardus Pruijn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting voor de Technische Wetenschappen STW
Original Assignee
Stichting voor de Technische Wetenschappen STW
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting voor de Technische Wetenschappen STW filed Critical Stichting voor de Technische Wetenschappen STW
Priority to EP09155765A priority Critical patent/EP2071335A3/de
Publication of EP1693673A2 publication Critical patent/EP1693673A2/de
Publication of EP1693673A3 publication Critical patent/EP1693673A3/de
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Definitions

  • the present invention relates to a method of detecting autoantibodies from patients suffering from rheumatoid arthritis, using a peptide comprising a citrullin residue or analogue thereof.
  • a method according to the preamble is also known from the international patent application PCT/FR00/01857.
  • This publication describes the use of peptides derived from fibrin or fibrinogen, and which comprise citrullin or an analogue thereof for the detection of autoantibodies from patients suffering from rheumatoid arthritis.
  • PCT/EP98/07714 describes the use of synthetic peptides derived from (pro)fillagrin for the diagnosis of rheumatoid arthritis. This application also describes synthetic peptides derived from human vimentin, cytokeratin 1, cytokeratin 9 and other intermediary filament proteins.
  • the present invention provides a method as mentioned in the preamble, which method is characterized in that said autoantibodies are contacted with a peptide unit comprising the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrullin residue or an analogue thereof, G is the amino acid glycine and nonG is an amino acid other than glycine.
  • sera obtained from patients suffering from rheumatoid arthritis contain two different populations of antibodies.
  • the one population is reactive with XG peptide units such as have been described in the above-mentioned pre-published literature.
  • the population can in part be detected with the pre-published XG peptide units and for a still larger part when using the peptide units according to the present invention.
  • the other population of antibodies reacts with XnonG peptide units.
  • this population of antibodies has not yet been observed as such in the pre-published literature.
  • the majority of sera from patients suffering from rheumatoid arthritis comprise both populations of antibodies.
  • the peptide unit with the XnonG motif comprised a part not derived from natural proteins such as human (pro)fillaggrin, fibrin, or fibrinogen as well as the related proteins vimentin, and cytokeratin 1 and cytokeratin 9 or other related intermediary filament proteins.
  • PCT/EP98/07714 describes a filaggrin-derived XnonG peptide (IPG1249). It is cross-reactive with 3.3% of the sera from SLE patients and has a homology of 82% with filaggrine.
  • the peptide unit with the XnonG motif comprises a tripeptide, in which the central amino acid is citrullin or an analogue thereof, and that a selection is preferably made from XXK, XXY, KXI, MXR, RXY, WXK, MXH, VXK, NXR, WXS, RXW,YXM, IXX, XXF, RXH, TXV, PXH, AXF, FXR, YXF, LXM, LXY, YXP, HXS and PXW.
  • nonG is an amino acid selected from H, I, W, S, R, K, Y, M, F, V, P, Cit or an analogue thereof. As shown in the experiments below, such XnonG peptide units are very effective.
  • the peptide unit comprising the XG motif may or may not be derived from (pro)filaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 or cytokeratin 9, and effectively the cfc1 known from PCT/NL97/00624.
  • amino acid includes both natural and non-natural amino acids, as well as amino acids having a D-configuration or L-configuration.
  • a non-natural amino acid is understood to be an amino acid of the kind occurring in an retro-inverso peptide, retro-peptide, a peptide wherein the side chain is located on the amide nitrogen atom of the peptide skelet, and a peptide wherein a CO of the peptide skelet is replaced by 2, 3 or preferably a single -CH 2- group (pseudo-peptide).
  • Amino acids may also be modified.
  • carboxylic acid groups may be esterified or may be converted to an amide, and an aminogroup may be alkylated, for example methylated.
  • functional groups on the peptide may be provided with a protective group or a label (for example a fluorescent or radioactive label).
  • Aminogroups and carboxylic acid groups in the peptides may be present in the form of a salt formed by using an acid or a base. If synthetic peptides are used, it is very simple to make all kinds of variants falling within the scope of the invention that can be used.
  • aromatic side groups such as from fenylalanine and tyrosine may be halogenated with one or more halogen atoms.
  • Peptidomimetic and organomimetic embodiments also fall within the scope of the invention and their application in the method according to the invention.
  • an analogue thereof such as those represented in Fig. 1 in the form of the amino acid.
  • Such analogues and their preparation are known to the person skilled in the art.
  • Sonke et al. in Stereoselective Biocatalysis (2000), pp. 23-58, and Greene: Protective groups in Organic synthesis (Wiley, New York 1999.
  • the side chains of the citrullin analogues have the formula (I): wherein
  • a peptide unit is understood to be a peptide that is at least 7 amino acids long.
  • Peptide units may have one or more side chains.
  • peptide units or terminal ends of the peptide unit may be acetylated, glycosylated, alkylated, or phosphorylated independently of each other.
  • a peptide unit in this context is indicated as not derived from (pro)filaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 or cytokeratin 9 and other intermediary filament proteins if the homology (the similarity of the amino acid sequence) to these proteins is less than 80%, more preferably less than 75% such as less than 70% or 65%, and most preferably less than 60%, such as less than 55% or 50%.
  • the peptide units shown in Table 5, which are not derived from (pro)filaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratine 9, have a homology between 15 and 45%. On examination of the homology arginine, citrullin and analogues of citrullin are considered to be equivalent (identical).
  • the peptide units comprising XG and XnonG may or may not part of the same molecule. This will be entered into later on.
  • the peptide units may be bound to a carrier and optionally provided with a label.
  • the complex may be detected in any manner well-known to the ordinary person skilled in the art.
  • the complex may be detected indirectly, for example in the case of a competition assay, in which the complex itself is not labelled.
  • the reaction with the two peptide units may take place simultaneously or successively and in the same container (such as a well of a microtitre plate) or in different containers.
  • the peptide units are recognized by at least 2 of 100 random sera from recognized RA patients. Obviously it is preferred to use peptide units that are recognized by a considerably higher percentage, preferably at least 30%.
  • the number of peptide units in a method according to the invention is preferably 2 or greater than 2.
  • the invention relates to a method as mentioned above, wherein the peptide unit with the XG motif and peptide unit with the XnonG motif are recognized together by at least 10% of the series of sera from patients.
  • the peptide unit with the XG motif and peptide unit with the XnonG motif are recognized together by at least 10% of the series of sera from patients.
  • combinations of peptide units resulting in higher sensitivities are preferred.
  • diagnostic tests can be carried out with sensitivities of 40, 60, 70, 80 or even 85 and more than 90%.
  • the sensitivity of the detection can be further increased if at least one of the peptide units is a cyclic peptide unit.
  • a multipeptide is a molecule comprised of at least two antigenic peptide units, i.e. combinations of peptide units that may or may not be linked by a covalent bond.
  • Such multipeptides may be comprised of linear, branched, cyclic peptide units or a combination of these.
  • Multipeptides may be comprised both of peptide units having the same amino acid sequence, and of peptide units having different amino acid sequences.
  • a multipeptide according to the invention comprises at least 7, preferably at least 10 amino acids, i.e. the peptide units may overlap. It goes without saying that the XG and XnonG motif can not overlap.
  • the invention also relates to a XnonG peptide unit, very useful for the method according to the present invention, comprising a sequence with the formula (II): (A1-A2-A3-A4-A5)-Cit-(A6)-(A7-A8-A9-A10-A11) (II) wherein
  • the invention also relates to a XnonG peptide unit, very useful for the method according to the present invention, comprising a sequence with the formula (III): (B1-B2-B3-B4-B5-B6)-Cit-(B7)-(B8-B9-B10-B11) (III) wherein
  • homologous sequence as used in connection with A1-A2-A3-A4-A5, A7-A8-A9-A10-A11, B1-B2-B3-B4-B5-B6 and B8-B9-B10-B11, means that at most two amino acids of each amino acid sequence may be replaced by as many other amino acids (including citrullin and/or an analogue thereof), at most two amino acids (including or an analogue thereof) may be introduced and at most two amino acids may be absent.
  • A6 and B7 are preferably selected from Cit, H, I, K, R, S, W, Y, M, F, V and P.
  • Specific preferred peptides to be used in the method according to the invention are characterized in that they comprise at least one peptide sequence selected from R H G R Q Cit Cit K Y I I Y I R Cit Y K Cit I T N R K F R H G R Q Cit Cit Cit Y I I Y A R F Q M Cit H Cit R L I R Q Cit Y K W Cit K I E R K R K P Y T V Cit K F M R K P K P Y T V Cit K F M R R P R N L R L Cit R E R N H A R R R R Cit Y Cit R A V I T A R F K S N Cit R T P N R W R G K S N Cit R T Y N R W R F K S N Cit R T Y N R W R G K S N Cit R T P N R W R W V S Q Cit R R T P T R M K P R Y Cit R I V V V K S F V W Cit S H A R P R Y S F V W Cit S H A R P R Y S F V
  • Suitable XG peptides to be used in the method according to the invention preferably comprise the sequence with the formula (IV) (C1-C2)-(C3-C4-C5)-X-G-C6-(C7-C8-C9-C10) (IV) wherein C1-C2 is HQ, GF, EG or GV; C3-C4-C5 represents 3 amino acids of which at least 1, and preferably 2 independently of each other are basic, aromatic or V; C6 is equal to a basic or aromatic amino acid, or equal to A, G, E, P, V, S or Cit or analogue thereof; and C7-C8-C9-C10 is SRAA, SCitAA, RPLD, RVVE or PGLD; as well as analogues of the peptide with the formula (IV).
  • the term 'analogue' as used in connection with the peptide of the formula (IV) means that optionally
  • XG peptides suitable to be used in the method according to the invention comprise a sequence selected from H Q R K W Cit G A S R A A H Q H W R Cit G A S R A A H Q F R F Cit G Cit S R A A H Q E R R Cit G E S R A A H Q K W R Cit G F S R A A H Q R W K Cit G G S R A A H Q R R T Cit G G S R A A H Q R R G Cit G S R A A H Q Cit F S A Cit G H R P L D H Q E R G Cit G K S R A A H Q E K R Cit G K S R A A H Q E K R Cit G K S R A A H Q R W L Cit G K S R A A H Q K R N Cit G K S R A A E G G G V Cit G P R V V E H Q W R H Cit G R S Cit A A H Q K W N Cit G R S R A A H Q K W N Cit G R S R A A E G G G V Cit G P R V V E H Q
  • the peptides according to the invention are preferably cyclic peptides of which the ring comprises at least 10 amino acids, and more preferably at least 11 amino acids.
  • the person skilled in the art is acquainted with various methods for the preparation of cyclic peptides and a further explanation is not required.
  • an XG peptide is used in combination with at least one XnonG peptide, wherein the XG peptide is selected from the group comprised of: 0002-27 H Q K R G Cit G W S R A A 0002-29 H Q R R V Cit G W S R A A 0002-31 H Q R R T Cit G G S R A A 0002-32 H Q R K W Cit G A S R A A 0002-36 H Q F R F Cit G Cit S R A A 0002-37 H Q K W R Cit G R S Cit A A 0002-63 H Q F R F Cit G W S R A A and the XnonG peptide is chosen from the group comprised of: 0107-32 K P Y T V Cit K F M R R P 0107-35 A R F Q M Cit H Cit R L I R 0107-45 Y S F V W Cit S H A R P R 0113-30 A R F Q M R H Cit R L I R 0218-36 R N L R L Cit R E R
  • a preferred combination of XG and XnonG peptide units is selected from the group comprised of: 0002-27 and 0107-32; 0002-27 and 0107-35;0002-27 and 0107-45; 0002-27 and 0113-30; 0002-27 and 0218-36;0002-29 and 0107-32; 0002-29 and 0107-35; 0002-29 and 0107-45;0002-29 and 0113-30; 0002-29 and 0218-36; 0002-31 and 0107-32;0002-31 and 0107-35; 0002-31 and 0107-45; 0002-31 and 0113-30;0002-31 and 0218-36; 0002-32 and 0107-32; 0002-32 and 0107-35;0002-32 and 0107-45; 0002-32 and 0113-30; 0002-32 and 0218-36;0002-36 and 0107-32; 0002-36 and 0107-35; 0002-36 and 0107-35; 0002-36 and 0107-35; 0002-36 and 0107-35; 0002-36 and 0107
  • the invention also relates to a multipeptide, characterized in that it is a linear or branched multi peptide, comprising at least two linear or cyclic peptide sequences selected independently of each other from
  • Such a multipeptide is very suitable for use in the method according to the invention. It makes it possible to carry out the method more simply and more reliably since peptides are used in the same known ratio, and extra operations during the assay or during the preliminary work (e.g. coating a microtitre plate with multipeptide) is avoided.
  • the invention further relates to a diagnostic kit for determining the presence of autoantibodies from patients suffering from rheumatoid arthritis, wherein the diagnostic kit comprises a peptide according to one of the claims 5 to 13, or a multipeptide according to claim 14, or a mixture thereof, together with at least one further reagent.
  • the invention also relates to a peptide or an antibody of an immunotoxin molecule as described above, or a composition thereof for use as a pharmaceutical composition.
  • the present invention further relates to a peptide or an antibody of an immunotoxin molecule as described above or a composition thereof for preparing a pharmaceutical composition or a diagnostic agent for rheumatoid arthritis.
  • the present invention also relates to the application of a peptide or a composition thereof as described above for preparing a pharmaceutical composition for the treatment of autoimmune diseases by increasing the size of antigen immune complexes, which improves the clarification of the immune complexes formed.
  • the present invention therefore also relates to a method for the treatment of rheumatoid arthritis by introducing into the body of a patient requiring such treatment, at least one peptide according to the invention.
  • the invention further relates to a method for the selection of a peptide suitable for the diagnosis of RA, wherein a peptide library is screened with antibodies obtained from patients with RA and wherein the peptide library is selected from a group comprised of:
  • the invention relates to a peptide that can be obtained with the aid of the afore-mentioned method to be used in a diagnostic assay.
  • a pharmaceutical composition for the treatment or "a drug for the treatment” or “the use of proteins for the preparation of a drug for the treatment” relate to a composition comprising a peptide as described above or an antibody binding specifically to the peptide and a pharmaceutically acceptable carrier or excipient (the two terms are interchangeable) for the treatment of diseases as described above.
  • Suitable carriers or excipients with which the ordinary person skilled in the art is familiar are saline, Ringer's solution, dextrose solution, Hank's solution, oils, ethyloleate, 5% dextrose in saline, substances improving isotonicity and chemical stability, buffers and preservatives.
  • suitable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, such as proteins, polysaccharides, polylactic acids, polyglycol acids, polymeric amino acids and amino acid polymers.
  • the "drug" may be administered in any manner known to the ordinary person skilled in the art.
  • the peptides according to the invention may be labelled (radioactive, fluorescent or otherwise, as well known in the art) or may be provided with a carrier. In this form also such peptides fall within the scope of the invention.
  • a peptide may be coupled to a carrier protein, such as Keyhole Limpet Haemocyanin or bovine serum albumin.
  • the peptide according to the invention may be non-covalently or covalently coupled to a solid carrier, such as a microsphere (gold, polystyrene etc.), slides, chips, or a wall of a reactor vessel or of a well of a microtitre plate.
  • the peptide may be labelled with a direct or an indirect label. Examples include biotin, fluorescein and an enzyme, such as horseradish peroxidase. All this is generally known to the ordinary person skilled in the art and requires no further explanation.
  • Citrullinated peptides were synthesised as described by De Koster H.S. et al. (J. Immunol. Methods, 187, pp. 177-188, (1995)). Beads were used to which the peptide molecules were attached via an amide bond so that after the removal of protective groups, peptide molecules were still attached to the bead.
  • an automated multiple peptide synthesiser was used (Abimed AMS422, Abimed, Langenfeld, Germany).
  • the incorporated amino acids and the peptide linker 6-aminohexane acid were protected by a Fmoc-group, and to facilitate coupling, the protected amino acids were activated with PyBOP and N-methylmorpholine.
  • the side chains were protected with groups protecting acid-sensitive side chains.
  • the beads used had a diameter of approximately 100 ⁇ m and comprised approximately 100 pmol peptide each. It is estimated that approximately 0.5% of this amount is bound to the outside and is in principle accessible to antibodies.
  • Example 2 Reaction of the bead-coupled peptides with sera from patients suffering from rheumatoid arthritis (RA)
  • IgG was isolated from serum from patients clinically diagnosed to be suffering from RA.
  • the beads were incubated with a solution comprising i) total serum from the patient, or ii) IgG from a patient conjugated to a reporter enzyme (alkaline phosphatase labelling kit; Roche/Boehringer, Mannheim, Germany).
  • a reporter enzyme alkaline phosphatase labelling kit; Roche/Boehringer, Mannheim, Germany.
  • serum i) a second incubation was carried out with an alkaline phosphatase conjugated anti-human IgG antibody (Dako D0336; Dako Immunoglobulins, Glostrup, Denmark). After each incubation the beads were thoroughly washed with Tris-HCl buffer pH 8.9 (50 mM Tris pH 8.9, 150 mM NaCl, 0.5% Tween® 20).
  • the beads with peptides that had bound the most human IgG (after dying with a substrate of alkaline phosphatase that is converted into an insoluble coloured product, these become the most intensely coloured beads) were selected with the aid of a microscope.
  • An XG peptide unit being preferably recognized by RA sera may therefore be represented by: -3 -2 -1 0 +1 +2 K R R X G R R W W E K
  • peptides described below were cyclisized in accordance with the cysteine-bromoacetic acid method.
  • Several cyclic variants were tested, with in particular the cyclic variants of peptides 0002-27, 0002-29, 0002-31, 0002-36, and 0002-63 proving to be of interest.
  • Ring size a number of adequately reacting peptides were used to synthesise additional cyclic peptides that each had a different ring size. Of these the 8, 9, 10, 11 and 12-mers were eventually tested. All these peptides were tested in ELISA with 48 RA sera and 8 normal sera respectively. The 8- and 9-mers reacted with some of the sera (with 22% (titre 0,47) and 28% (titre 0,5), respectively, but the titres (the OD-values found) were much lower than when larger rings were used (10-mer 33% with a titre van 0.60; 11- and 12-mer 50% with an average titre of 0.74. Table 2: Results from serum- analyses using cyclic peptide 0002-36.
  • the above table represents ELISAs with sera obtained from patients suffering from RA and from patients suffering from various other autoimmune diseases. This shows the high specificity of RA sera for a peptide such as 0002-36. Practically none of the cases showed sera obtained from other autoimmune diseases and material from normal healthy persons to be positive.
  • the arginine variant of peptide 0002-36 (R on position 0 and +2, i.e. instead of Cit in the formula) was also tested and shown to be negative with all tested RA and normal sera.
  • Table 3 ELISA with 132 RA sera with peptide 36 compared with peptide cfc1 from [PCT/NL97/00624]: peptide cfc1 (linear) cfc1 (cyclic) 0002-36 (linear) 0002-36 (cyclic) 48/132 83/132 80/132 94/132 positive sera 36% 63% 61% 71%
  • the cyclic variant was shown to react more frequently (and better) than the linear variant. Better, because the OD-values found with the cyclic variant were also much higher than with the linear composition.
  • the cyclic variant was created via -S-S-bonds between two cysteins, or via a thioether formed, for example, by reacting a cysteine and a bromoacetyl group (formed by reacting a thiol in the side chain of a cysteine with an N-terminal bromoacetyl group, forming a thioether), is immaterial.
  • the N-terminal bromoacetyl group is formed, after the synthesis of the peptide, by allowing the bead-bound peptide (peptidyl-resin) to react with the N-hydroxy succinimide ester of bromoacetic acid) in the same peptide.
  • XnonG peptides mentioned all reacted with one or more XG-negative sera For example, peptides 0107-32, 0107-35, and 0107-45 react with approximately 15-18% of the XG negative sera.
  • a XnonG peptide unit preferably recognized by RA sera may be represented by: -5 -4 3 -2 -1 0 +1 +2 +3 +4 +5 R R R R R X R R R R R N Y V Q H T I I K F I Y Y P P H S V N G
  • peptide 0107-35 in the cyclic form reacts with 18% of the sera that are not reactive with cyclic 0002-36.
  • This sensitivity may be further increased by other peptides.
  • a further 8% may be added by cyclic peptide 0107-32.
  • a similar value was found for the peptide 0107-45.
  • XG-negative sera were shown to react with one or more XnonG peptides.
  • a sensitivity of above 80% can be achieved. This is therefore better than what can be achieved by a combination of the peptides with the formula IV, and those known from PCT/NL97/00624.
  • the sensitivity can be increased even further by using more peptides still.
  • a cyclic XG peptide for example 0002-63 or 0002-36
  • a linear or cyclic XnonG peptide for example 0107-35
  • 318 RA sera a sensitivity of 78% was obtained.
  • the addition of a 3rd, 4th and possibly 5th peptide increased the sensitivity to 85% (peptides 0107-32, 0107-42 respectively 0107-34).
  • a mere 48 of the 318 RA sera did not react with one of the peptides mentioned.
  • Example 7 Sensitivity and specificity of diagnostic tests comprising XG and XnonG peptide units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Amplifiers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP06114882A 2001-12-11 2002-12-11 Nachweis von Autoantikörpern von Pantienten mit rheumatischer Arthritis Ceased EP1693673A3 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09155765A EP2071335A3 (de) 2001-12-11 2002-12-11 Nachweis von Autoantikörpern von Pantienten mit rheumatischer Arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1019540A NL1019540C2 (nl) 2001-12-11 2001-12-11 Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit.
EP02786237A EP1456662B1 (de) 2001-12-11 2002-12-11 Nachweis von autoantikörpern von patienten mit rheumatischer arthritis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP02786237A Division EP1456662B1 (de) 2001-12-11 2002-12-11 Nachweis von autoantikörpern von patienten mit rheumatischer arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP09155765A Division EP2071335A3 (de) 2001-12-11 2002-12-11 Nachweis von Autoantikörpern von Pantienten mit rheumatischer Arthritis

Publications (2)

Publication Number Publication Date
EP1693673A2 true EP1693673A2 (de) 2006-08-23
EP1693673A3 EP1693673A3 (de) 2006-12-06

Family

ID=19774384

Family Applications (3)

Application Number Title Priority Date Filing Date
EP09155765A Withdrawn EP2071335A3 (de) 2001-12-11 2002-12-11 Nachweis von Autoantikörpern von Pantienten mit rheumatischer Arthritis
EP06114882A Ceased EP1693673A3 (de) 2001-12-11 2002-12-11 Nachweis von Autoantikörpern von Pantienten mit rheumatischer Arthritis
EP02786237A Expired - Lifetime EP1456662B1 (de) 2001-12-11 2002-12-11 Nachweis von autoantikörpern von patienten mit rheumatischer arthritis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09155765A Withdrawn EP2071335A3 (de) 2001-12-11 2002-12-11 Nachweis von Autoantikörpern von Pantienten mit rheumatischer Arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP02786237A Expired - Lifetime EP1456662B1 (de) 2001-12-11 2002-12-11 Nachweis von autoantikörpern von patienten mit rheumatischer arthritis

Country Status (17)

Country Link
US (6) US7888133B2 (de)
EP (3) EP2071335A3 (de)
JP (1) JP4098718B2 (de)
CN (4) CN105699648B (de)
AT (1) ATE329267T1 (de)
AU (3) AU2002354397B2 (de)
BR (1) BRPI0214872B8 (de)
CA (5) CA2489167C (de)
CY (1) CY1105537T1 (de)
DE (1) DE60212186T2 (de)
DK (1) DK1456662T3 (de)
ES (1) ES2266603T3 (de)
HK (4) HK1072805A1 (de)
NL (1) NL1019540C2 (de)
PT (1) PT1456662E (de)
SI (1) SI1456662T1 (de)
WO (1) WO2003050542A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402368A1 (de) 2010-07-02 2012-01-04 Toscana Biomarkers S.r.l. Histoncitrullinierte Peptide und deren Verwendungen
EP2527841A1 (de) 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Verfahren zur Diagnose rheumatoider Arthritis

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1019540C2 (nl) 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit.
PT1882946E (pt) * 2003-12-23 2010-04-21 Roche Diagnostics Gmbh Método para avaliar artrite reumatóide através da medição de anti-ccp e interleucina 6
ES2314621T3 (es) 2004-02-27 2009-03-16 F. Hoffmann-La Roche Ag Procedimiento de evaluacion de la artritis reumotoidea, mediante la medicion de anti-ccp y amiloide a serico.
FR2879604B1 (fr) * 2004-12-22 2010-08-13 Biomerieux Sa Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations
ATE401338T1 (de) 2004-11-04 2008-08-15 Biomerieux Sa Von fibrin abgeleitete citrullinpeptide, die durch für rheumatoide arthritis spezifische autoantikörper erkannt werden, und deren verwendung
EP1877795A4 (de) * 2005-05-02 2010-04-28 Brigham & Womens Hospital Diagnostische profilerstellung von serumantikörpern
FI20050814A0 (fi) * 2005-08-11 2005-08-11 Procollagen Oy Menetelmä nivelreumassa muodostuvien kollageeniautovasta-aineiden havaitsemiseksi
ES2545688T3 (es) 2006-09-29 2015-09-15 F. Hoffmann-La Roche Ag Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide
US20100047256A1 (en) 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
ES2307421B1 (es) 2007-04-30 2009-09-28 Consejo Superiorde Investigaciones Cientificas (Csic) Polipeptido quimerico fibrina-filagrina citruinado capaz de detectar los anticuerpos generados en la artritis reumatoide.
EP2058663A1 (de) 2007-11-12 2009-05-13 Euro-Diagnostica B.V. Verfahren zur Immobilisierung eines Analyts auf einem festen Träger
WO2009070875A1 (en) * 2007-12-03 2009-06-11 Sqi Diagnostics Systems Inc. Synthetic peptides immuno-reactive with rheumatoid arthritis auto-antibodies
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2204655A1 (de) 2008-12-23 2010-07-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnostische Prognose von rheumatoider Arthritis und systemischem Lupus erythematodes
FR2940292B1 (fr) * 2008-12-23 2013-05-10 Isp Investments Inc Peptides derives d'hmg-coa reductase et composition cosmetique et/ou pharmaceutique les contenant
CN102004154B (zh) * 2009-08-28 2013-06-19 上海荣盛生物药业有限公司 斑点金免疫渗滤法检测类风湿关节炎免疫抗体的组合物
CN102012431B (zh) * 2009-09-04 2013-06-19 上海荣盛生物药业有限公司 斑点金免疫渗滤法检测类风湿关节炎免疫抗体的ccp肽
EP2325195A1 (de) 2009-11-23 2011-05-25 Toscana Biomarkers S.r.l. Virale citrullinierte Peptide und Verwendungen dafür
EP2336769A1 (de) 2009-12-18 2011-06-22 F. Hoffmann-La Roche AG Assay zur Unterscheidung zwischen rheumatischen und nicht rheumatischen Leiden
ES2535743T3 (es) * 2011-02-02 2015-05-14 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Anticuerpos antiproteína carbamilada y el riesgo de padecer artritis
EP2694530B1 (de) 2011-04-05 2018-02-14 Curara AB Neue peptide zur bindung an einzelne typen der mhc-klasse-ii und ihre verwendung bei diagnose und behandlung
EP2715360B1 (de) * 2011-05-27 2016-08-17 Nordic Bioscience A/S Nachweis von diagnostischen peptiden
CN102590530B (zh) * 2012-03-02 2014-06-25 常晓天 Krt84自我免疫抗体作为诊断、检测类风湿性关节炎的诊断标记物的应用
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド
US20160159922A1 (en) 2013-07-24 2016-06-09 Vilara Ab Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis
DK3140323T3 (en) 2014-05-05 2018-07-23 Novio Th B V METHOD OF SEROLOGICAL DIAGNOSTICATION OF RHEUMATOID ARTHRITIS.
CN104262489B (zh) * 2014-09-30 2017-01-11 陈仁奋 一种环状瓜氨酸嵌合肽抗原及其应用
JP2018506720A (ja) 2015-02-13 2018-03-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｃｃｐおよび抗ｐｉｋ３ｃｄを測定することによる関節リウマの査定方法
EP3056903A1 (de) 2015-02-13 2016-08-17 F. Hoffmann-La Roche AG Verfahren zur Beurteilung rheumatoider Arthritis mittels Messung von Anti-CCP und Anti-Casp8
EP3056904A1 (de) 2015-02-13 2016-08-17 F. Hoffmann-La Roche AG Verfahren zur Beurteilung rheumatoider Arthritis mittels Messung von Anti-CCP und Anti-MCM3
US20180313830A1 (en) * 2015-10-30 2018-11-01 Oxford University Innovation Ltd. Peptide and biomarker associated with inflammatory disorders, and uses thereof
CN110073217A (zh) 2016-10-04 2019-07-30 豪夫迈·罗氏有限公司 用于鉴定合成分类器的系统和方法
CN106543277B (zh) * 2016-10-31 2020-02-14 中南大学 一种与移植排斥相关的内皮细胞抗原及其应用、试剂盒
CN108196073B (zh) * 2018-03-13 2019-09-13 江苏浩欧博生物医药股份有限公司 一种测定抗环瓜氨酸肽抗体的试剂盒及其应用
CN108948153B (zh) * 2018-05-22 2020-11-03 北京蛋白质组研究中心 一种瓜氨酸修饰肽抗原组合及其应用
CN108948173B (zh) * 2018-05-22 2020-11-03 北京蛋白质组研究中心 一种瓜氨酸修饰肽及其应用
WO2020151631A1 (zh) * 2019-01-27 2020-07-30 中国医药大学 一种类风湿性关节炎自体抗体结合的肽及其应用
CN109929009B (zh) * 2019-03-20 2021-06-04 深圳市新产业生物医学工程股份有限公司 Ccp肽段、包含其的抗原、试剂、试剂盒及应用
WO2020221153A1 (zh) * 2019-04-28 2020-11-05 广州市雷德生物科技有限公司 一种促进蛋白二聚体形成的拉链扣结构及其应用
CN111655734A (zh) * 2019-04-28 2020-09-11 广州市雷德生物科技有限公司 一种促进蛋白二聚体形成的拉链扣结构及其应用
CN110456074B (zh) * 2019-08-27 2022-06-03 广东菲鹏生物有限公司 瓜氨酸肽及其应用、类风湿关节炎的检测试剂与试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022503A2 (en) * 1996-11-15 1998-05-28 Stichting Scheikundig Onderzoek Nederland Peptide derived from an antigen recognized by autoantibodies from patients with rheumatoid arthritis, antibody directed against said peptide, a combinatorial antigen, and a method of detecting auto-immune antibodies
WO1999028344A2 (en) * 1997-11-28 1999-06-10 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
WO1999035167A1 (fr) * 1997-12-30 1999-07-15 Biomerieux Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233366T2 (de) * 1991-04-26 2005-05-19 Biomerieux S.A. Antigene, die von Polyarthritis Rheumatoide Antikörpern erkannt werden, ihre Herstellung und ihre Anwendungen
US5610297A (en) * 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
CN1153530A (zh) * 1995-03-09 1997-07-02 比奥美希奥公司 相关于类风湿性关节炎的msrv-1病毒和致病性和/或感染性msrv-2因子
KR0182853B1 (ko) * 1995-08-07 1999-05-15 김신규 자가면역 질환의 진단 방법
FR2752842B1 (fr) * 1996-08-30 1998-11-06 Biomerieux Sa Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide
GB9805477D0 (en) * 1998-03-13 1998-05-13 Oxford Glycosciences Limited Methods and compositions for diagnosis of rheumatoid arthritis
GB9822115D0 (en) * 1998-10-09 1998-12-02 King S College London Treatment of inflammatory disease
FR2795735B1 (fr) 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
AU2012301A (en) * 1999-12-21 2001-07-03 Innogenetics N.V. Peptides designed for the diagnosis and treatment of rheumatoid arthritis
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
NL1019540C2 (nl) 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022503A2 (en) * 1996-11-15 1998-05-28 Stichting Scheikundig Onderzoek Nederland Peptide derived from an antigen recognized by autoantibodies from patients with rheumatoid arthritis, antibody directed against said peptide, a combinatorial antigen, and a method of detecting auto-immune antibodies
WO1999028344A2 (en) * 1997-11-28 1999-06-10 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
WO1999035167A1 (fr) * 1997-12-30 1999-07-15 Biomerieux Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIRBAL-NEUHAUSER, ELISABETH ET AL: "The epitopes targeted by the rheumatoid arthritis -associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues" JOURNAL OF IMMUNOLOGY, 162(1), 585-594, 1999, XP002101364 *
SCHELLEKENS GERARD A ET AL: "The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide." ARTHRITIS & RHEUMATISM, vol. 43, no. 1, January 2000 (2000-01), pages 155-163, XP008018548 ISSN: 0004-3591 *
SCHELLEKENS, GERARD A. ET AL: "Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis -specific autoantibodies" JOURNAL OF CLINICAL INVESTIGATION, 101(1), 273-281, 1998, XP000749589 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402368A1 (de) 2010-07-02 2012-01-04 Toscana Biomarkers S.r.l. Histoncitrullinierte Peptide und deren Verwendungen
WO2012001103A1 (en) 2010-07-02 2012-01-05 Toscana Biomarkers S.R.L. Histone citrullinated peptides and uses thereof
EP2527841A1 (de) 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Verfahren zur Diagnose rheumatoider Arthritis
WO2012160127A1 (en) 2011-05-25 2012-11-29 Toscana Biomarkers S.R.L. Method for the diagnosis of rheumatoid arthritis

Also Published As

Publication number Publication date
US20070087380A1 (en) 2007-04-19
ATE329267T1 (de) 2006-06-15
AU2006230702A1 (en) 2006-11-09
US20190056393A1 (en) 2019-02-21
US8759114B2 (en) 2014-06-24
NL1019540C2 (nl) 2003-07-01
DK1456662T3 (da) 2006-09-18
CN101408546A (zh) 2009-04-15
US10119966B2 (en) 2018-11-06
EP2071335A3 (de) 2009-09-02
US20140336069A1 (en) 2014-11-13
BR0214872A (pt) 2004-10-26
CA2708463C (en) 2015-08-11
CN100424509C (zh) 2008-10-08
AU2002354397A1 (en) 2003-06-23
CA3076702C (en) 2022-03-29
BRPI0214872B1 (pt) 2016-12-13
EP1456662B1 (de) 2006-06-07
EP1456662A2 (de) 2004-09-15
US7888133B2 (en) 2011-02-15
CA3076702A1 (en) 2003-06-19
CA2708463A1 (en) 2003-06-19
AU2002354397B2 (en) 2006-07-20
CY1105537T1 (el) 2010-07-28
CN1602426A (zh) 2005-03-30
AU2010200648A1 (en) 2010-03-11
CA2489167C (en) 2010-08-10
US20130267677A1 (en) 2013-10-10
JP2005512092A (ja) 2005-04-28
US8481332B2 (en) 2013-07-09
HK1226143B (zh) 2017-09-22
CN101408546B (zh) 2013-10-30
CA2969577A1 (en) 2003-06-19
JP4098718B2 (ja) 2008-06-11
US20110195861A1 (en) 2011-08-11
CA2489167A1 (en) 2003-06-19
WO2003050542A3 (en) 2003-12-11
ES2266603T3 (es) 2007-03-01
AU2010200648B2 (en) 2012-07-12
CA2892001C (en) 2017-07-18
CN103524603B (zh) 2016-02-24
CN105699648B (zh) 2017-10-20
HK1128329A1 (en) 2009-10-23
DE60212186T2 (de) 2007-04-12
CN105699648A (zh) 2016-06-22
PT1456662E (pt) 2006-10-31
HK1072805A1 (en) 2005-09-09
HK1191962A1 (zh) 2014-08-08
US20170269078A1 (en) 2017-09-21
BRPI0214872B8 (pt) 2021-07-27
WO2003050542A2 (en) 2003-06-19
SI1456662T1 (sl) 2006-12-31
DE60212186D1 (de) 2006-07-20
US9689871B2 (en) 2017-06-27
CN103524603A (zh) 2014-01-22
EP1693673A3 (de) 2006-12-06
EP2071335A2 (de) 2009-06-17
CA2969577C (en) 2020-04-14
CA2892001A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
US10119966B2 (en) Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and assay kit
US6277583B1 (en) Affinity labeling libraries and applications thereof
AU772851B2 (en) Therapeutic and diagnostic domain 1 beta2GPI polypeptides and methods of using same
WO2000005250A1 (en) Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
Schleifer et al. The Immunochemistry of Peptidoglycan: I. THE IMMUNODOMINANT SITE OF THE PEPTIDE SUBUNIT AND THE CONTRIBUTION OF EACH OF THE AMINO ACIDS TO THE BINDING PROPERTIES OF THE PEPTIDES
Hochhaus et al. the k-Opioid Receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1456662

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

17P Request for examination filed

Effective date: 20070222

17Q First examination report despatched

Effective date: 20070419

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130725